STRIDES ARCOLAB AND LILLY ENTER STRATEGIC PARTNERSHIP TO
DELIVER HIGH-QUALITY, BRANDED GENERIC CANCER MEDICINES FOR
EMERGING MARKETS

Under the partnership agreement, Lilly will have the rights to market cancer medicines across the emerging markets

New Delhi and Bangalore, India, December 5, 2012: Eli Lilly and Company and Strides Arcolab Limited today announced a collaboration to expand delivery of cancer medicines in the emerging markets. As a part of this arrangement, Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab, based in Bangalore, India.

Agila Specialties will manufacture the cancer medicines, and Lilly will register and market these medications in multiple geographies across the emerging markets. In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high-quality branded generic oncology products to the portfolio in the future.

“Cancer medicines of the highest quality continue to be an unmet need in many markets around the world. Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets.” said Jacques Tapiero, Lilly Senior Vice President and President of its emerging markets division.

Arun Kumar, Founder & Group CEO of Strides Arcolab said, “We are delighted to partner with Lilly to expand its branded generics platform with high-quality oncology products that will benefit from Lilly’s strong global presence in key markets.”

Commenting on the occasion, Melt Van Der Spuy, Managing Director, Lilly India said, “This strategic partnership marks Lilly India’s entry into branded generics, reaffirming our commitment to reach more Indian patients. We believe this partnership will help us build a significantly larger and more meaningful presence in the Indian cancer segment, and hence, enable us to better serve many more Indian patients suffering from various forms of cancer.”
About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., USA, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

About Agila Specialties

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest sterile capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at www.stridesarco.com.

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>Eli Lilly and Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. V.S. Iyer, CEO - Agila</td>
<td>Shikha Arora: 9811237987</td>
</tr>
<tr>
<td>+91 80 6784 0111</td>
<td><a href="mailto:arora_shikha@lilly.com">arora_shikha@lilly.com</a></td>
</tr>
<tr>
<td>Mr. Ajay Singh : +91 80 6784 0813</td>
<td></td>
</tr>
<tr>
<td>Mr. Kannan N : +91 98450 54745</td>
<td></td>
</tr>
<tr>
<td>(Investors)</td>
<td>Eli Lilly and Company India Pvt. Ltd</td>
</tr>
</tbody>
</table>

**PR Consultancy**

Corporate Voice | Weber Shandwick
Mahesh Nair,
+91 9880376648 ; maheshn@corvoshandwick.co.in

Kaveri Mandanna,
+91 90089 59697; kaveri@corvoshandwick.co.in